Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

A New Era of Precision Medicine in Gynecologic Cancers
  • CME

Credits Available
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: July 15, 2021 Expiration: July 14, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
GlaxoSmithKline
Robert L. Coleman, MD, FACOG, FACS
Linda R. Duska, MD, MPH
Leslie M. Randall, MD, MAS, FACS

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss the underlying molecular biology of gynecologic cancers and potential targets for therapy
  • Evaluate current and emerging practice-changing clinical data on checkpoint inhibitors and PARP inhibition as single-agent or combination therapies in cervical, endometrial, and ovarian cancers
  • Plan treatment strategies for patients with cervical, endometrial, and ovarian cancers that incorporate novel therapies and combination strategies
  • Select maintenance therapy for patients with ovarian cancer with or without BRCA mutations or other homologous recombination repair deficiencies in the frontline and relapsed settings
  • Describe the role of immune checkpoint inhibitor–based therapy in endometrial cancer classified as microsatellite stable

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Robert L. Coleman, MD, FACOG, FACS

Gynecologic Oncologist & Chief Scientific Officer
US Oncology, US Oncology Research
The Woodlands, Texas

Robert L. Coleman, MD, FACOG, FACS, has disclosed that he has received consulting fees from AbbVie, Agenus, Alkermes, Aravive, AstraZeneca, Clovis, Deciphera, Epsilogen, Genmab, Immunogen, Merck, Novocure, and Roche/Genentech; funds for research support from AbbVie, AstraZeneca, Clovis, Genmab, Immunogen, Merck, and Roche/Genentech; and fees for non-CME/CE services from AstraZeneca.
Leslie M. Randall, MD, MAS, FACS

Diane Harris Wright Professor and Director
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Massey Cancer Center
Virginia Commonwealth University
Richmond, Virginia

Leslie M. Randall, MD, MAS, has disclosed that she has received consulting fees from Agenus, AstraZeneca, Clovis Oncology, EMD Serono, Genentech/Roche, Merck, Mersana, Myriad Genetics, Novocure, and Rubius; fees for non-CME/CE services from AstraZeneca, Merck, and Tesaro; and funds for research support paid to her institution from Aivita, Akeso, AstraZeneca, Genentech/Roche, Merck, On Target Laboratories, Pfizer, and Tesaro.
Linda R. Duska, MD, MPH

Gynecologic Oncologist
Department of OB GYN/Gynecologic Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Linda R. Duska, MD, MPH, has disclosed that she has received consulting fees from CUE Biopharma, Genentech/Roche, and Merck; has received funds for research support paid to her institution from AbbVie, Aduro, Advaxis, Aeterna Zentaris, Bristol-Myers Squibb, Cerulean, Genentech/Roche, GlaxoSmithKline, Leap Therapeutics, Ludwig, Merck, Millennium, Morab, Morphotek, Novartis, Pfizer, Seagen, Syndax, and Tesaro; and has received other financial or material support from Inovio.

Staff

Jerfiz Constanzo, PhD, MBA
Scientific Director
Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.
Jill Sakai, PhD

Editorial Contributor

Jill Sakai, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for medical oncologists, gynecologic oncologists, and other healthcare professionals who treat patients with cervical, endometrial, and ovarian cancers.

Goal

The goal of this program is to improve the knowledge and competence of learners in gynecologic malignancies.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 15, 2021, through July 14, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

A New Era of Precision Medicine in Gynecologic Cancers
  • CME

Loading...
Watch this on-demand webcast from a live CCO webinar where top experts reviewed the latest advances in gynecologic cancer management and discuss novel therapies in development for endometrial, ovarian, and cervical cancers.
Robert L. Coleman, MD, FACOG, FACS
Linda R. Duska, MD, MPH
Leslie M. Randall, MD, MAS, FACS
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: July 15, 2021 Expiration: July 14, 2022

Related Content

Prof Nicole Concin, MD, PhD, shares her thoughts on the application of new clinical data for ovarian and endometrial cancers in Europe in this clinical commentary from Clinical Care Options (CCO)

Nicole Concin, MD, PhD Released: December 7, 2021

Clinical commentary with Colleen Bohnenkamp, PharmD, BCOP, BCPS, and Dane Fritzsche, PharmD, BCOP, on application of new clinical data for ovarian and endometrial cancers in Europe, from Clinical Care Options (CCO)

person default Colleen Bohnenkamp, PharmD, BCOP, BCPS person default Dane Fritzsche, PharmD, BCOP Released: December 7, 2021

Downloadable short slideset from CCO on recognizing and managing ocular toxicities associated with antibody–drug conjugates.

Asim V. Farooq, MD Joann Kang, MD Paul G. Richardson, MD Released: November 29, 2021

Podcast episode with expert insights on important trial data for ovarian and endometrial cancers from the ESGO 2021 annual meeting, from Clinical Care Options (CCO)

Nicole Concin, MD, PhD Released: November 23, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
GlaxoSmithKline

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue